Review



mk2206  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    MedChemExpress mk2206
    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, <t>MK2206</t> (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.
    Mk2206, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 328 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mk2206/product/MedChemExpress
    Average 96 stars, based on 328 article reviews
    mk2206 - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalance"

    Article Title: CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalance

    Journal: bioRxiv

    doi: 10.64898/2026.01.20.700699

    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, MK2206 (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.
    Figure Legend Snippet: ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, MK2206 (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.

    Techniques Used:



    Similar Products

    mk2206  (MedChemExpress)
    96
    MedChemExpress mk2206
    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, <t>MK2206</t> (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.
    Mk2206, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mk2206/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    mk2206 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    p akt inhibitor mk2206  (MedChemExpress)
    96
    MedChemExpress p akt inhibitor mk2206
    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, <t>MK2206</t> (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.
    P Akt Inhibitor Mk2206, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p akt inhibitor mk2206/product/MedChemExpress
    Average 96 stars, based on 1 article reviews
    p akt inhibitor mk2206 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    akt inhibitor mk2206  (MedChemExpress)
    97
    MedChemExpress akt inhibitor mk2206
    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, <t>MK2206</t> (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.
    Akt Inhibitor Mk2206, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/akt inhibitor mk2206/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    akt inhibitor mk2206 - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    mk2206  (TargetMol)
    94
    TargetMol mk2206
    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, <t>MK2206</t> (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.
    Mk2206, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mk2206/product/TargetMol
    Average 94 stars, based on 1 article reviews
    mk2206 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, MK2206 (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.

    Journal: bioRxiv

    Article Title: CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalance

    doi: 10.64898/2026.01.20.700699

    Figure Lengend Snippet: ( A-E ) In the DSS-based αCTLA-4-induced colitis model, anti-mouse IL-17A neutralizing antibody (200 μg/mouse) was administered intraperitoneally at D0, D3, D6, and D9 (n=5). Body weight monitoring (A), DAI score monitoring (A), colon length measurement (B), endpoint tumor volume (C) and tumor weight (D) detection, representative colon H&E results and pathological score statistics (E). ( F-I ) In the DSS-based αCTLA-4-induced colitis model, MK2206 (p.o.; 30 mg/kg/day), Rapamycin (i.p.; 5 mg/kg/day), and 2-DG (i.p.; 500 mg/kg/day) were administered from D0 to D10 (n=6). Body weight monitoring (F), DAI score monitoring (F), colon length measurement (G), endpoint tumor volume (H) and tumor weight (H) detection, representative colon H&E results and pathological score statistics (I). The data are presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; ns not significant by one-way ANOVA followed by Tukey’s multiple comparisons test.

    Article Snippet: In the DSS-based αCTLA-4-induced colitis model, MK2206 (p.o.; 30 mg/kg/day; HY-108232, MCE), Rapamycin (i.p.; 5 mg/kg/day; HY-10219, MCE), and 2-DG (i.p.; 500 mg/kg/day; HY-13966, MCE) were administered from D0 to D10.

    Techniques: